This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side...

Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI ), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phase I testing of PR-15 to treat acute...

Europe’s biotech sector has reached a stage of maturity where companies need to raise substantial amounts of money to support product development. In recent years, VCs have stepped up to the plate, with top-tier privates...

Germany's Jerini has been tipped as a potential European IPO for more than a year, but the company has always maintained that it would go when the climate was right. The company has decided that...

Trigen (London, U.K.) raised EUR 26.5 million ($32.1 million) in its first round of funding since merging with ProCorde in April. The round was led by Wellington Partners; HealthCap; and 3i. Other investors included SR...

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...

European takeouts Completed Acquirer Country Acquired Country Value Jan Paradigm Therapeutics U.K. Amedis U.K. Undisclosed Jan Sinclair Pharma (LSE:SPH) U.K. Euroderm RDC Italy E6M ($7.2M) in cash & stock Jan Solvay (Euronext:SOLB) Belgium NeoPharma Sweden...

Building sustainable biotech businesses when investors are playing hard to get is forcing European CEOs to think about making some hard choices. For some that means surrendering their independence, for others it means thinking about...